OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 03:42:16 2024-06-20 am EDT | ||
| 13.82 EUR | -0.93% |
|
| Current month | +8.48% | ||
| 1 month | +15.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 13.82 | -0.93% |
| 24-06-19 | 13.95 | -0.85% |
| 24-06-18 | 14.07 | -4.29% |
| 24-06-17 | 14.7 | -4.73% |
| 24-06-14 | 15.43 | +2.25% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 03:42 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC3NX5 |
| ISIN | DE000HC3NX58 |
| Date issued | 2023-01-30 |
| Strike | 317.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.59 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.19 € |
| Spread % | 1.36% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Certificates
- Certificat
